IRCT20170614034526N3 IRCT 2019-03-08 Jinnah Hospital, Lahore Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis. Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 3 in patients undergoing hemodialysis- A Prospective interventional clinical trial 2017-08-01 anticipated 36 Complete https://irct.ir/trial/37490 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Condition 1: Chronic Viral Hepatitis-C. Condition 2: Chronic kidney disease, stage 5. Intervention 1: Intervention group 1: Daclatasvir 60 mg + Sofosbuvir 400 mg once daily for 12 weeks. Intervention 2: Intervention group 2: Daclatasvir 60 mg per day and Sofosbuvir 400 mg 3 times / per week for 12 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is Data can be inspected by Institute Ethical review board for any reason, but public data sharing is not planned for this specific study..